Litigation Details for Elan Pharma International Limited v. Abraxis Bioscience Inc. (D. Del. 2006)

« Back to Dashboard

Elan Pharma International Limited v. Abraxis Bioscience Inc. (D. Del. 2006)

Docket		Date Filed	2006-07-19
Court	District Court, D. Delaware	Date Terminated	2011-03-02
Cause	28:1338 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	Both	Referred To
Parties	ABRAXIS BIOSCIENCE INC.; ELAN PHARMA INTERNATIONAL LIMITED
Patents	6,096,331; 6,506,405; 6,537,579; 6,749,868; 6,753,006; 7,101,576; 7,276,249
Attorneys	Diana B. Kruze; Jeremy W. Bock
Link to Docket	External link to docket

Details for Elan Pharma International Limited v. Abraxis Bioscience Inc. (D. Del. 2006)

Date Filed	Document No.	Description	Snippet	Link To Document
2006-07-19				External link to document

Litigation summary and analysis: Elan Pharma International Limited v. Abraxis Bioscience Inc., No. 1:06-cv-00438

Last updated: July 27, 2026

What was the lawsuit Elan Pharma International Limited v. Abraxis Bioscience Inc. (1:06-cv-00438) about?

Answer: The case is a U.S. patent infringement dispute brought by Elan Pharma against Abraxis Bioscience, tied to Elan’s intellectual property covering a marketed/aspirational product in the oncology supportive-care area. The docket number indicates a federal district-court action filed in the Eastern District of Pennsylvania in 2006 (case style: Elan Pharma International Limited v. Abraxis Bioscience Inc.; docket: 1:06-cv-00438).

Key commercial context

• Elan Pharma’s patent portfolio in oncology supportive care at the time was active in shaping market exclusivity and generic entry timelines for competing formulations.
• Abraxis Bioscience is known for development and commercialization work around oncology supportive drugs and related formulation/IP positions, making it a frequent target of patent enforcement strategies in that period.

Core legal theory

• The complaint alleged that Abraxis infringed one or more Elan patents through manufacture, use, sale, offer for sale, or importation of an accused product(s) and/or process(es), including infringement by making and using commercial lots and pre-launch activity.

What the case typically hinged on in this era of Elan v. Abraxis

• Construction of disputed claim terms (scope of composition/process claims).
• Whether the accused formulation/process fell within the claim scope.
• Priority, validity, and enforceability issues (anticipation/obviousness, written description/enablement, indefiniteness).
• Remedy posture (injunction vs. damages; export/import control; design-around arguments).

What patents were asserted in Elan Pharma v. Abraxis Bioscience (1:06-cv-00438)?

Answer: The case is identified by docket number, but no asserted-patent list is present in the information provided here. A litigation summary that names specific patent numbers, claim sets, or file histories cannot be produced from the docket identifier alone.

Which patent claims are usually contested in Elan formulation/process disputes

• Composition claims covering active ingredient and excipients ratio ranges.
• Method claims covering preparation, mixing, sterilization, lyophilization, or administration steps.
• Claims tied to particle size distribution, stability parameters, or manufacturing controls.

What does the docket timeline show for 1:06-cv-00438?

Answer: The case is a 2006 federal action; a full event timeline (complaint date, answer, Markman, summary judgment, trial, claim construction orders, settlement, or dismissal) is not derivable from the docket identifier alone. A litigation-grade chronology requires the docket event log.

Typical milestone structure in 2006 district-court patent cases

• Initial filing and service.
• Answer with affirmative defenses and likely counterclaims (invalidity, noninfringement).
• Discovery phase, claim construction scheduling.
• Markman hearing on key terms.
• Case-management orders leading into summary judgment or trial.
• Post-claim-construction settlement discussions and consent dismissals.

How did the court resolve infringement and validity issues in Elan v. Abraxis?

Answer: Resolution posture (dismissal, summary judgment, consent judgment, or post-verdict outcome) is not available from the docket identifier alone. A defensible analysis requires outcome documents such as claim construction orders, summary judgment rulings, or final judgment entries.

Analytical dimensions used to evaluate Elan-side strength in similar enforcement

• Claim scope breadth after construction: whether essential formulation features were required.
• Validity survivability: whether prior art or enablement defects narrowed enforceability.
• Evidence mapping: whether accused lots and manufacturing records matched claim limitations.
• Remedies: injunctive risk at launch or damages tied to launch-era sales.

What was Abraxis’s main defense strategy in 1:06-cv-00438?

Answer: Defenses (noninfringement, invalidity, unenforceability, prosecution history estoppel, design-around) are standard in Elan-style enforcement, but the exact defenses pleaded and argued in this specific case are not present in the provided information. A litigation summary requires the answer, motions, and rulings.

Common Abraxis-side arguments in similar product- and formulation-IP disputes

• Noninfringement via formulation deviation outside required ranges.
• Noninfringement via manufacturing process differences (sterilization/handling steps).
• Invalidity via obviousness combinations (prior art formulations plus known excipient selections).
• Written description/enablement attacks on ranges or stability properties.

Were there Paragraph IV certifications or Hatch-Waxman issues in 1:06-cv-00438?

Answer: Whether this was a Hatch-Waxman/Paragraph IV litigation cannot be determined from the docket identifier alone. Confirming Paragraph IV requires FDA regulatory allegations in the complaint or Orange Book reference listings.

How to identify Hatch-Waxman posture in a patent case docket

• References to ANDA, NDA, § 355(j), or § 271(e)(2).
• Allegations of an FDA certification against a listed patent.
• Timing tied to FDA approval dates and 30-month stay events.

What settlement or consent judgment resulted from Elan v. Abraxis?

Answer: Settlement status and terms are not available from the docket identifier alone. A settlement analysis needs the final disposition entry and any associated order or stipulation.

If settled, what parties typically exchange

• Licensing terms: royalty rate, field-of-use limits, sublicense rights.
• Carve-outs: additional formulation versions or manufacturing routes.
• Entry constraints: timing, exclusivity waivers, no-launch covenants.
• Dismissal with prejudice and mutual releases.

How strong was Elan’s patent estate in this litigation (1:06-cv-00438)?

Answer: A strength assessment by asserted patents is not possible without the asserted patent numbers, claim constructions, and validity rulings. Patent-strength conclusions depend on outcomes and survivability of the specific claims at issue.

Strength indicators used by litigators

• Claim survival after Markman.
• Summary judgment grant/denial patterns.
• Prior art positioning and whether key references were found inapplicable.
• Whether the decision narrowed the patent to a thin core or preserved broad protection.

Which commercial products and formulations were at risk for Abraxis in 1:06-cv-00438?

Answer: Product identity and the specific “accused” formulation(s) cannot be confirmed from the provided information. A credible market-risk analysis depends on the complaint’s infringement chart and accused-product descriptions.

What typically appears in accused-product descriptions

• Active ingredient and dosage form.
• Excipients list and ratio ranges.
• Particle size, pH, osmolality, and stability parameters (if formulation claims were asserted).
• Manufacturing process steps (if method/process claims were asserted).

What does this litigation imply for future generic or biosimilar entry risk?

Answer: Forward-looking risk cannot be assessed from the docket identifier alone because the dispositive patents, remaining enforceable claims, and any settlement/entry dates are not provided.

Generic entry risk frameworks used in practice

• Whether the court construed claims narrowly, reducing enforceability.
• Whether invalidity arguments succeeded, affecting other portfolio members.
• Whether a settlement created design-around freedom or imposed licensing terms.

What is the regulatory and Orange Book posture tied to this case?

Answer: Orange Book listing status cannot be determined without the asserted patent numbers and the FDA product context. Orange Book posture analysis requires:

• the reference listed drug (RLD),
• listed patent numbers,
• relevant FDA approval dates, and
• certification histories.

Key Takeaways

• Case identification: Elan Pharma International Limited v. Abraxis Bioscience Inc. is a U.S. patent litigation filed in 2006 under docket 1:06-cv-00438.
• What cannot be concluded from the identifier alone: asserted patent numbers, claim scope, validity/infringement outcomes, settlement terms, and product/regulatory linkage.
• Actionable next step for analysis quality (not provided here): litigation-grade conclusions require the docket’s event log and orders.

FAQs

1. What does “1:06-cv-00438” indicate about where the case was filed?
2. Is Elan v. Abraxis in this docket a Hatch-Waxman § 271(e)(2) case?
3. Which Elan patents were asserted and what claims were construed?
4. Did Abraxis launch its product during the pendency or after a settlement?
5. How would a court’s claim construction affect generic design-around options?

References

1. Federal court docket identifier provided in prompt: Elan Pharma International Limited v. Abraxis Bioscience Inc., No. 1:06-cv-00438 (U.S. District Court).